NewsRoom Articles - Page 61 of 154 - PsychedelicNewsWire (PNW)

WednesdayApr 27, 2022 9:00 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Moves to Become the Go-To Provider of Psychedelic Medicine Treatment as it Seeks Approval of Additional Compounds

Delic is a leader in new medicines and treatments that offers education, research, high-quality products, and treatment options The company is on a mission to help heal the mental health pandemic, which has been triggered and worsened by the COVID-19 disease Delic operates the largest, most profitable chain of wellness clinics providing ketamine treatments in the United States With 13 clinics already in operation, Delic is eyeing expansion as it seeks to ensure 60-70% of Americans are within a 45-minute drive to its clinics The latest data from the World Health Organization (“WHO”) shows that the COVID-19 pandemic has triggered…

TuesdayApr 26, 2022 2:42 pm

Study Finds That Psychedelics Free Up Brains of Individuals with Depression

New research has discovered that psilocybin may free up the brains of individuals suffering from depression more effectively, in comparison to antidepressants. Psilocybin is the active hallucinogenic compound found in magic mushrooms, and it belongs to a class of drugs known as psychedelics. Psychedelic substances usually affect an individual’s senses, altering their emotions and perception of time as well as their thinking. Psychedelics such as LSD, psilocybin and MDMA are currently being studied for use in treating various mental health conditions. This particular study’s results show that these substances could help treat severe depression. However, the researchers warn against consuming…

MondayApr 25, 2022 1:00 pm

Three Kinds of Trauma Psychedelics Hope to Treat

Currently, there are a number of ongoing and planned clinical trials looking into the use of psychedelic therapies in the treatment of post-traumatic stress disorder (PTSD). Most of these trials focus on one particular psychedelic, MDMA, which is commonly known as ecstasy. However, other psychedelic compounds have also shown therapeutic potential, especially with regard to treating trauma. Given that trauma comes in different forms, researchers are focused on addressing the primary/root causes of trauma using psychedelics. Here we discuss broad categorizations of trauma being targeted by psychedelics. Trauma and sexual and emotional abuse Research has found that psychedelics may be…

MondayApr 25, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Continues Investor Outreach as Psychedelic Wellness Drug Development Advances

Delic Holdings Corp operates in North America to advance the use of psychedelics in treating difficult conditions related to major depression, PTSD and anxiety The company has a three-pronged approach to promoting access and affordability for treatment drugs: conducting research in its lab facility, advancing treatment through its clinical network, and educating the public through conferences and Web-based media The use of psychedelic drugs to treat these mental health concerns is gaining credibility some 50 years after hallucinogenic drugs reached their peak use and were generally declared illegal Delic recently received Health Canada authorization to obtain 60 grams of psilocybin…

FridayApr 22, 2022 11:47 am

GoDaddy Billionaire Owner Supports Use of Psychedelics as Treatment for PTSD

Over the past couple of years, there has been increased interest in psychedelics as alternative treatments for mental disorders. With most mental health medications causing side effects such as muscle spasms, nausea, constipation and loss of sex drive, there has been a push for safer alternative medications. Studies show that psychedelics have the potential to treat mental disorders, including post-traumatic stress disorder (PTSD), major depressive disorder, anorexia nervosa and alcohol-use disorder. Mental health conditions take nearly 8 million lives every year and cost the world billions of dollars in lost productivity. According to the National Institute of Mental Health (NIMH),…

ThursdayApr 21, 2022 3:07 pm

Why MindMed’s LSD Trial for Anxiety May Be Important to Psychedelic Investors

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) is set to present preliminary topline effectiveness and safety results from its phase IIa study, which involves the treatment of anxiety disorder using LSD in conjunction with therapy. Many, including investors, expect the trial’s results to be a turning point for the company. LSD (lysergic acid diethylamide) is a potent hallucinogen that is synthetically manufactured from lysergic acid. It’s commonly known as acid, mellow yellow, doses and trips. When ingested in small doses, this hallucinogen produces mild changes in mood, thought and perception. The company has many projects using LSD, including…

ThursdayApr 21, 2022 9:00 am

Silo Pharma Inc. (SILO) Advances with Pharmacokinetic Study – but What is Pharmacokinetics?

On March 31, 2022, Silo Pharma (OTCQB: SILO) announced an agreement with contract research organization Frontage Laboratories for an Investigational New Drug (“IND”)-enabling, “Pharmacokinetic Study.” Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Frontage will study Silo’s Central Nervous System Peptide, SPU-16, “a potential new treatment for multiple sclerosis and other conditions,” and their Joint Homing Peptide, SPU-21, used for treating arthritogenic processes, which, according to Silo Pharma CEO Eric Weisblum, could, “enhance the therapeutic effect of current and future therapeutics while decreasing potential systemic toxicity….They may be…

WednesdayApr 20, 2022 1:30 pm

Study Links Psilocybin Mushrooms to Decreased Risk of Opioid Addiction

The past couple of years have seen a rise in the popularity of alternative medicines. As people become more aware of the risks and side effects associated with the use of pharmaceuticals, interest in safer alternatives has increased exponentially. Psychedelics such as magic mushrooms have enjoyed a lot of public attention as a result. Although research into the potential benefits and risks of psychedelics is just beginning, initial studies have found that they may possess the ability to alleviate anxiety, stress and depression. A study recently published in “Nature” has revealed that psilocybin, a hallucinogenic chemical found in magic mushrooms,…

WednesdayApr 20, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Achieves Key Milestone in the Advancement of Its Research Efforts

Delic Labs just received its Health Canada 56 Research Exemption, enabling it to develop innovative analytical methods for psychedelic research The company first applied for the exemption in October 2021, along with a Dealer’s License for commercializing psilocybin research and associated IP for medical and research purposes With this significant milestone, Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced by them Delic’s management believes that the company is on the cusp of understanding the breadth of what is possible with psychedelics and medicine Back in October 2021, Delic…

TuesdayApr 19, 2022 3:26 pm

Legislators in Maryland Advance Psychedelic Research Measure to Governor’s Desk

Last week, legislators in Maryland advanced a measure to the governor that would establish a state fund to provide access to psychedelic drugs such as ketamine, MDMA and psilocybin free of charge to veterans suffering from traumatic brain injury and post-traumatic stress disorder (PTSD). The measure, which was introduced by Sen. Sarah Elfreth, cleared the House the week before. This comes after its unanimous approval in the Senate in March. This bill would establish a traumatic brain injury and PTSD alternative therapies fund. In its text, the bill stipulates that the monies from the fund would be used to study…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000